Arsenal Biosciences Inc. advanced its lead product candidate into clinical manufacturing of its autologous integrated circuit T-cell therapy for platinum-resistant ovarian cancer. ArsenalBio’s work to develop multi-functional CAR-T cell therapies is enabled by Thermo Fisher’s Cell Therapy Systems portfolio of products, including the Gibco CTS Xenon Electroporation System and the Gibco CTS Rotea Counterflow Centrifugation System.
Thermo Fisher Scientific announced the latest recipients of the Oncomine Clinical Research Grant, designed to support emerging research on molecular profiling in oncology and to help democratize the future of precision medicine.
